DrugPatentWatch Database Preview

Tris Pharma Inc Company Profile

« Back to Dashboard

What is the competitive landscape for TRIS PHARMA INC, and what generic alternatives to TRIS PHARMA INC drugs are available?

TRIS PHARMA INC has twenty-six approved drugs.

There are seven US patents protecting TRIS PHARMA INC drugs.

There are nineteen patent family members on TRIS PHARMA INC drugs in fourteen countries and nineteen supplementary protection certificates in eight countries.

Summary for Tris Pharma Inc

International Patents:	19
US Patents:	7
Tradenames:	25
Ingredients:	24
NDAs:	26
Drug Master File Entries:	5
Patent Litigation for Tris Pharma Inc:	See patent lawsuits for Tris Pharma Inc

Drugs and US Patents for Tris Pharma Inc

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Tris Pharma Inc	LEVETIRACETAM	levetiracetam	SOLUTION;ORAL	090461-001	Sep 30, 2010	AA	RX	No	No
Tris Pharma Inc	HYDROCODONE BITARTRATE AND ACETAMINOPHEN	acetaminophen; hydrocodone bitartrate	TABLET;ORAL	202214-001	Mar 27, 2013	AA	RX	No	No
Tris Pharma Inc	TUZISTRA XR	chlorpheniramine polistirex; codeine polistirex	SUSPENSION, EXTENDED RELEASE;ORAL	207768-001	Apr 30, 2015		DISCN	Yes	No	8,790,700		Y
Tris Pharma Inc	TUZISTRA XR	chlorpheniramine polistirex; codeine polistirex	SUSPENSION, EXTENDED RELEASE;ORAL	207768-001	Apr 30, 2015		DISCN	Yes	No	8,062,667		Y

Non-Orange Book US Patents for Tris Pharma Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
9,549,989	Modified release formulations containing drug-ion exchange resin complexes
9,675,704	Modified release formulations containing drug-ion exchange resin complexes
8,202,537	Modified release formulations containing drug-ion exchange resin complexes
8,491,935	Modified release formulations containing drug-ion exchange resin complexes

International Patents for Tris Pharma Inc Drugs

Country	Document Number	Estimated Expiration
Taiwan	200812649
World Intellectual Property Organization (WIPO)	2007109104
Russian Federation	2435569
Japan	5479086

Supplementary Protection Certificates for Tris Pharma Inc Drugs

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
C0026	France		PRODUCT NAME: RALTEGRAVIR OU L(UN DE SES SELS PHARMACEUTIQUEMENT ACCCEPTABLES EN PARTICULIER UN SEL DE POTASSIUM; REGISTRATION NO/DATE IN FRANCE: EU/1/07/436/001 DU 20071220; REGISTRATION NO/DATE AT EEC: EU/1/07/436/001 DU 20071220
00085	Netherlands		PRODUCT NAME: LEVOCETIRIZINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER LEVOCETIRINE DIHYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 26770 20011009; FIRST REGISTRATION: DE 49903.00.00 AND 49904.00.00 20010103
C0008	Belgium		PRODUCT NAME: RISPERIDONE; NAT REG.: 2 S 414 F 3 19940527; FIRST REG.: GB 0242/0186 19921208
2013 00059	Denmark		PRODUCT NAME: KOMBINATION AF (A) DEXTROMETHORPHAN OG (B) QUNIDIN, HERUNDER DEXTROMETHORPHANHYDROBROMIDMONOHYDRAT OG QUINIDINSULFATDIHYDRAT; REG. NO/DATE: EU/1/13/833 20130624

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Tris Pharma Inc